Daniel Lynch is an executive venture partner at GVteam. They are Chairman of the Board for Xilio Therapeutics (2020–Present), Translate Bio (2012–Present), bluebird bio (2011–Present), SpringWorks Therapeutics (2017–Present), and Blueprint Medicines (2012–Present). Their prior leadership roles included Executive Chairman at Stromedix Inc. (2007–2012) and Nimbus Discovery (2012–2015), and Chairman of the Board at BIND Therapeutics (2012–2016) and Surface Oncology Inc. (2017–2021); they also served as CEO of ImClone Systems (2001–2005) and Board Member at Ember Therapeutics (2012–2013) and Edimer Pharmaceuticals (2011–2013). They earned an MBA from Darden Business School (1982–1984) and a BA in Mathematics from Wesleyan University (1976–1980).
This person is not in the org chart
This person is not in any teams
This person is not in any offices